Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

ABSTRACT:

Background

Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated with the clinical benefit and toxicity of ipilimumab, baseline characteristics and changes in CD4(+) and CD8(+) T cells from melanoma patients receiving ipilimumab were characterized by gene profiling and flow cytometry.

Methods

Microarray analysis of flow-cytometry purified CD4(+) and CD8(+) T cells was employed to assess gene profiling changes induced by ipilimumab. Selected molecules were further investigated by flow cytometry on pre, 3-month and 6-month post-treatment specimens.

Results

Ipilimumab up-regulated Ki67 and ICOS on CD4(+) and CD8(+) cells at both 3-

SUBMITTER: Wang W 

PROVIDER: S-EPMC3527361 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature